If you have or haven't looked at the ICH E6 revision 3 GCP guideline, this may be of interest to see how others perceive the differences from the current guideline.
From the LinkedIn announcement:
TransCelerate is excited to announce the release of a new co-created resource! We have partnered with the Association of Clinical Research Organizations (ACRO) to release a new infographic that features the key changes to risk management in ICH E6 (R3) between Version 2 and 3.
#goodclinicalpractice #acceleratinganswers #collaboration #ICH #E6(R3) #GCP
Learn more and check out the new infographic: https://lnkd.in/gGC-fJtR
------------------------------
Mark Arnold Ph.D., FAAPS
Westampton, NJ
[email protected]Bioanalytical Solution Integration
LinkedIn:
https://www.linkedin.com/in/markearnoldphd/Website & Blog: Bioanalysis & Biomarkers <bioanalysisandbiomarkers.blogspot.com>
------------------------------
</bioanalysisandbiomarkers.blogspot.com>